Overview

Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The main objective is to investigate if the brain activation signature of a typical antipsychotic agent is dissociable from a newer drug with a pharmacological profile that differs from both typical and atypical antipsychotics since it is a potent partial D2 agonist. The method used to study this will be functional magnetic resonance imaging (fMRI).
Phase:
Phase 4
Details
Lead Sponsor:
Oslo University Hospital
Treatments:
Aripiprazole
Haloperidol
Haloperidol decanoate